Search research articles
Contact Us
Filters
Showing results (491-500 of 523) with videos related to
Page
of 53
Sort By:
RMD Open
|
February 22, 2024
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
Laura C Coates, Robert Landewé, Iain B McInnes, et al.
Journal of the American Academy of Dermatology
|
March 16, 2019
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management
Ali Alikhan, Christopher Sayed, Afsaneh Alavi, et al.
Journal of the American Academy of Dermatology
|
March 16, 2019
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management
Ali Alikhan, Christopher Sayed, Afsaneh Alavi, et al.
Lancet (London, England)
|
December 10, 2022
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
Joseph F Merola, Robert Landewé, Iain B McInnes, et al.
JAMA Dermatology
|
May 18, 2017
Pediatric Psoriasis Comorbidity Screening Guidelines
Emily Osier, Audrey S Wang, Megha M Tollefson, et al.
The British Journal of Dermatology
|
February 7, 2019
Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa
L Thorlacius, A Garg, P T Riis, et al.
The British Journal of Dermatology
|
May 11, 2018
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis
C Ryan, A Menter, L Guenther, et al.
American Journal of Clinical Dermatology
|
August 3, 2005
Long-term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of photodamaged facial skin: a two-year, randomized, placebo-controlled trial
Sewon Kang, Wilma Bergfeld, Alice B Gottlieb, et al.
Journal of the American Academy of Dermatology
|
July 25, 2000
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?
G G Krueger, S R Feldman, C Camisa, et al.
Lancet (London, England)
|
May 25, 2024
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
Alexa B Kimball, Gregor B E Jemec, Christopher J Sayed, et al.
Page
of 53
Search research articles
Search
Showing results (491-500 of 523) with videos related to
Sort By:
Page
of 53
RMD Open
|
February 22, 2024
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
Laura C Coates, Robert Landewé, Iain B McInnes, et al.
Journal of the American Academy of Dermatology
|
March 16, 2019
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management
Ali Alikhan, Christopher Sayed, Afsaneh Alavi, et al.
Journal of the American Academy of Dermatology
|
March 16, 2019
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management
Ali Alikhan, Christopher Sayed, Afsaneh Alavi, et al.
Lancet (London, England)
|
December 10, 2022
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
Joseph F Merola, Robert Landewé, Iain B McInnes, et al.
JAMA Dermatology
|
May 18, 2017
Pediatric Psoriasis Comorbidity Screening Guidelines
Emily Osier, Audrey S Wang, Megha M Tollefson, et al.
The British Journal of Dermatology
|
February 7, 2019
Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa
L Thorlacius, A Garg, P T Riis, et al.
The British Journal of Dermatology
|
May 11, 2018
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis
C Ryan, A Menter, L Guenther, et al.
American Journal of Clinical Dermatology
|
August 3, 2005
Long-term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of photodamaged facial skin: a two-year, randomized, placebo-controlled trial
Sewon Kang, Wilma Bergfeld, Alice B Gottlieb, et al.
Journal of the American Academy of Dermatology
|
July 25, 2000
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?
G G Krueger, S R Feldman, C Camisa, et al.
Lancet (London, England)
|
May 25, 2024
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
Alexa B Kimball, Gregor B E Jemec, Christopher J Sayed, et al.
Page
of 53